Chen SK, et al. - Using claims data from Truven MarketScan database (2006–2015), individuals with RA aged ≥ 18 years with ≥ 2 RA diagnoses who began treatment with abatacept or a tumor necrosis factor inhibitor (TNFi) were recognized in order to assess the comparative risk of hospitalized infection among people with RA who started abatacept vs a TNFi. A total of 11,248 propensity score-matched pairs of individuals who began treatment with abatacept and TNFi were enrolled. Results of this large cohort of people with RA who began treatment with abatacept or TNFi as a first- or second-line biologic agent, a lower risk of hospitalized infection subsequent to beginning abatacept compared with TNFi was discovered, which was pushed principally by infliximab.